German PEI approves enrolment in cohort 5 of Oncolytics’ pancreatic cancer trial
The Paul-Ehrlich-Institute (PEI) in Germany has granted approval to continue subject enrolment in cohort 5 of Oncolytics Biotech’s GOBLET trial,…
Oncology
-
-
Pfizer’s Phase III bladder cancer therapy trial meets primary endpoint
Pfizer's Phase III CREST trial evaluating sasanlimab with Bacillus Calmette-Guérin (BCG), as induction treatment with or without maintenance in subjects…
-
Sanofi reports positive results from trial of multiple myeloma drug candidate
French pharmaceutical company Sanofi has reported results from its Phase III IRAKLIA trial, which evaluated Sarclisa (isatuximab) as a potential…
-
Samsung Biologics and LigaChem extend ADC services deal
Samsung Biologics has extended its collaboration with LigaChem Biosciences for antibody-drug conjugate (ADC) services. The partnership will leverage Samsung Biologics'…
-
Chugai and Araris enter $780m ADC research collaboration
Chugai Pharmaceutical and Araris Biotech have entered an antibody-drug conjugate (ADC)-focused research collaboration and option-to-license agreement worth up to $780m.…
-
J&J reports positive topline outcomes from Phase III NSCLC combo therapy trial
Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant (amivantamab-vmjw) and Lazcluze…
-
FDA awards GSK breakthrough status for relapsed osteosarcoma treatment
GSK has gained US Food and Drug Administration (FDA) breakthrough therapy designation (BTD) for its B7-H3-targeted antibody-drug conjugate (ADC), GSK'227,…
-
I-Mab pauses CD73 antibody development in pipeline reshuffle
Cancer immunotherapy biotech I-Mab, has paused the development of uliledlimab in favour of its now lead candidate givastomig. The Maryland,…
-
Mass General Brigham reports results from trial of skin cancer prevention therapy
Investigators at Mass General Brigham in Massachusetts, US, have reported outcomes from a study of a new immunotherapy for skin…
-
Hanx Biopharmaceuticals doses first subject in trial of therapy for solid tumours
Chinese biotechnology company Hanx Biopharmaceuticals has dosed the first subject in the Phase I trial of HX044, a bispecific antibody…
